Which treatment is NOT typically indicated for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)?

Nadolol, an oral beta-blocker, is commonly used to prevent arrhythmias in patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). By blocking the effects of adrenaline on the heart, nadolol helps to mitigate the risk of arrhythmias triggered by physical activity or emotional stress. Exercise restriction is an essential part of management for CPVT, as it helps to prevent episodes of tachycardia, especially during physical exertion, which is known to trigger symptoms in affected individuals. An implantable cardioverter defibrillator (ICD) is also indicated for patients at high risk of life-threatening arrhythmias, providing a means to restore normal heart rhythm if dangerous tachycardia occurs.

Long-term anticoagulation, however, is not typically indicated for CPVT. This treatment is generally used to prevent thromboembolic events in conditions associated with atrial fibrillation or other arrhythmias that can lead to blood clots. Since CPVT does not inherently pose a risk for these types of events, long-term anticoagulation is not part of standard management for this condition.